Results 1 to 10 of about 2,806 (137)

Mixed cryoglobulinemia; a rare presentation of Waldenström macroglobulinemia [PDF]

Journal of Nephropathology, 2022
Type II mixed cryoglobulinemia is a systemic disease mediated by immune complexes. Renal involvement is present in almost one third of the cases and the membranoprolifer-ative pattern is the most common histological presentation.
Catarina Isabel Ribeiro, Clara Santos, Clara Almeida, Teresa Melo, David Tente, João Carlos Fernandes   +5 more
doaj   +1 more source

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +1 more source

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

eJHaem, 2022
The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib.
Jorge J. Castillo, Shayna Sarosiek, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. Treon   +7 more
doaj   +1 more source

Bilateral central retinal vein occlusion as an initial presentation of Waldenström macroglobulinemia: a case report

Journal of Medical Case Reports, 2023
Background Waldenström macroglobulinemia is a rare hematological malignancy and is the most common diagnosis in patients with hyperviscosity syndrome.
Suraj Shrestha, Elisha Poddar, Bibhav Bashyal, Aayush Adhikari, Prabin Pathak, Suman Acharya, Surendra Sapkota, Anjan Bhattarai, Samriddha Raj Pant, Anjan Shrestha   +9 more
doaj   +1 more source

Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia

Therapeutic Advances in Hematology, 2021
The pathological increase of clonal IgM in Waldenström macroglobulinemia can be associated with acquired von Willebrand syndrome and can be a major risk of bleeding symptoms in this subgroup of patients with Waldenström macroglobulinemia.
María Poza, Rodrigo Íñiguez, Irene Zamanillo, Sara Redondo, Rafael Alonso, Joaquín Martínez-López, Ana Jiménez-Ubieto   +6 more
doaj   +1 more source

A rare clinical presentation of Waldenström Macroglobulinemia mimicking lung cancer

Respiratory Medicine Case Reports, 2022
Waldenström macroglobulinemia rarely presents as pulmonary symptoms, and even rarer as chylothorax. We present a patient who presented with bilateral pleural effusion and a 30 mm solid lesion in the lung.
Michael RT. Laursen, Shailesh Kolekar, Pradeesh Sivapalan, Paul F. Clementsen, Uffe Bodtger   +4 more
doaj   +1 more source

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenström Macroglobulinemia

Blood, 2018
Abstract Although estrogens have been shown to regulate normal B cell proliferation and differentiation, the impact of estrogen receptor (ER) signaling on B cell malignancies, including Waldenström Macroglobulinemia (WM), remains unexplored.
Nicola Amodio, Giada Juli, Eugenio Morelli, Maria Angelica Stamato, Maria Eugenia Gallo Cantafio, Cinzia Federico, Katia Todoerti, Emanuela Altomare, Katia Grillone, Marco Rossi, Michele Cea, Antonino Neri, Mariateresa Fulciniti, Nikhil Munshi, Pierosandro Tagliaferri, Pierfrancesco Tassone   +15 more
openaire   +1 more source

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients

Blood, 2018
Abstract BACKGROUND: Standard rituximab plus chemotherapy salvage treatment has shown moderate activity in patients with relapsed/refractory Waldenström's macroglobulinemia (RR-WM), with 18-months progression free survival (18-PFS) of about 50%.
Giulia Benevolo, Simone Ferrero, Alessandro Andriani, Anna Castiglione, Anna Baraldi, Carola Boccomini, Maria Giuseppina Cabras, Catello Califano, Federica Cavallo, Annarita Conconi, Luigi Curreli, Daniela Drandi, Gianluca Gaidano, Stefano Felici, Martina Ferrante, Donato Mannina, Michele Merli, Anna Lia Molinari, Pellegrino Musto, Gerardo Musuraca, Francesca Gaia Rossi, Roberto Sartori, Monica Tani, Marzia Varettoni, Umberto Vitolo, Lorella Orsucci   +25 more
openaire   +1 more source

Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance

Haematologica, 2017
We analyzed MYD88 and CXCR4 mutation status of 260 patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance using allele-specific real time quantitative polymerase chain reaction and Sanger sequencing ...
Marzia Varettoni, Silvia Zibellini, Irene Defrancesco, Virginia Valeria Ferretti, Ettore Rizzo, Luca Malcovati, Anna Gallì, Matteo Giovanni Della Porta, Emanuela Boveri, Luca Arcaini, Chiara Candido, Marco Paulli, Mario Cazzola   +12 more
doaj   +1 more source

Multimodal Imaging of Waldenstrom Macroglobulinemia-Associated Hyperviscosity-Related Retinopathy Treated with Plasmapheresis

Case Reports in Ophthalmological Medicine, 2021
While plasmapheresis is well known to significantly improve both retinal findings and systemic manifestations associated with Waldenstrom macroglobulinemia, few reports exist documenting changes in optical coherence tomography angiography (OCT-A).
Michael J. Schatz, Carl S. Wilkins, Oscar Otero-Marquez, Toco Y. P. Chui, Richard B. Rosen, Meenakashi Gupta   +5 more
doaj   +1 more source